Recent Research Analysts’ Ratings Changes for LENSAR (LNSR)

A number of firms have modified their ratings and price targets on shares of LENSAR (NASDAQ: LNSR) recently:

• 8/23/2026 – LENSAR was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/21/2026 – LENSAR was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 8/20/2026 – LENSAR had its price target raised by BTIG Research from $9.00 to $10.00. They now have a “buy” rating on the stock.
• 8/15/2026 – LENSAR was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/13/2026 – LENSAR had its “buy” rating reaffirmed by Lake Street Capital. They now have a $13.00 price target on the stock.
• 8/13/2026 – LENSAR had its price target raised by BTIG Research from $7.00 to $9.00. They now have a “buy” rating on the stock.
• 8/7/2026 – LENSAR had its “sell (d+)” rating reaffirmed by Weiss Ratings.

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.